Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia
Haemophilia · 2025
DOI: 10.1111/hae.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Deborah Obeng-Tuudah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Katharine Dormandy Haemophilia and Thrombosis Centre, The Royal Free NHS Hospital and Institute for Women's…. Hauptthemen laut MEDLINE: Thrombasthenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Royal Free Charity research fund, Novo Nordisk Health Care AG.
Abstract (Originalsprache)
Introduction
Glanzmann's thrombasthenia (GT) is an inherited platelet function disorder that may manifest with significant bleeding symptoms; in women and girls (W&Gs), heavy menstrual bleeding (HMB) is very common. GT in pregnancy is associated with an increased risk of postpartum haemorrhage (PPH).
Aim
This study highlights the gynaecological and obstetric challenges experienced by W&Gs with GT, and reviews available treatment options.
Methods
Data regarding 38 W&Gs with GT were analysed from the ISTH REDCap registry, an international multi‐centre database.
Results
Among 38 W&Gs, 76% of Middle Eastern ethnicity, 100% reported HMB; 92% HMB since menarche, and 82% presented with acute HMB and were treated with platelets and packed red blood cells (pRBCs) transfusions in addition to hormonal therapies. Management of chronic HMB required a combination therapy including antifibrinolytics (tranexamic acid [TXA]), hormonal therapies, and recombinant factor VIIa (rFVIIa); rFVIIa was used in 50% of W&Gs. In 16 pregnancies, PPH was reported in 63% of deliveries, of which 83% required blood and platelet transfusions. Despite prophylactic haemostatic agents during labour and delivery in 8/9 pregnancies of women with known GT diagnosis, 78% experienced PPH. Thirty‐one percent of neonates developed neonatal alloimmune thrombocytopenia (NAIT).
Conclusion
HMB and PPH are common bleeding complications in GT. Effective management of HMB and PPH in W&Gs with GT is challenging but can be achieved by a multidisciplinary team, often requiring a combination of haemostatic agents with hormonal therapies. Use of rFVIIa may limit the need for platelet transfusion, thus reducing alloimmunisation and the risk of developing NAIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Katharine Dormandy Haemophilia and Thrombosis Centre, The Royal Free NHS Hospital and Institute for Women's Health, University College London, London, UK.
- Madinah Hereditary Blood Disorders Center, King Salman Medical City, Madinah, Saudi Arabia.
ORCID-Profile: Rezan Abdul-Kadir
Förderung
- Royal Free Charity research fund
- Novo Nordisk Health Care AG
Zitieren
APA
Obeng-Tuudah, D., Tarawah, A., Ozkan, M., & Abdul-Kadir, R. (2025). Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia. Haemophilia. https://doi.org/10.1111/hae.70030
Vancouver
Obeng-Tuudah D, Tarawah A, Ozkan M, Abdul-Kadir R. Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia. Haemophilia. 2025. doi:10.1111/hae.70030
BibTeX
@article{ObengTuudah2025,
author = {Obeng-Tuudah, Deborah and Tarawah, Ahmad and Ozkan, Melike and Abdul-Kadir, Rezan},
title = {Obstetric and Gynaecological Challenges and Outcomes in Women and Girls With Glanzmann's Thrombasthenia},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70030}
}
EUVIMED